检索结果-南通市图书馆

Cellular & Molecular Immunology 2023年第11期20卷 1393-1394页

作者： Jianshu Wei Xin Lin weidong han Changping Laboratory Yard 28Science Park RoadChangping District102206BeijingChina Department of Basic Medical Sciences Tsinghua University School of Medicine100084BeijingChina Tsinghua-Peking Center for Life Sciences 100084BeijingChina Department of Biotherapy the First Medical CenterChinese PLA General Hospital100853BeijingChina

CAR T-cell therapy has shown remarkable potential in the treatment of hematologic malignancies,and these successes have greatly motivated research on treatment of solid tumors.Although numerous clinical trials have been actively carried out,exciting clinical responses are still sporadic and may be are transient for patients with solid tumors[1].

关键词： clinical treatment transient

Inducing immunogenic cell death in immuno-oncological therapies

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2022年第1期34卷 1-10页

作者： Dongdong Ti Xin Yan Jianshu Wei Zhiqiang Wu Yao Wang weidong han Department of Bio-therapeutic the First Medical CenterChinese PLA General HospitalBeijing 100853China

Immunotherapy has revolutionized cancer treatment and substantially improved patient outcomes with respect to multiple types of tumors.However,most patients cannot benefit from such therapies,mainly due to the intrinsic low immunogenicity of cancer cells(CCs)that allows them to escape recognition by immune cells of the body.Immunogenic cell death(ICD),which is a form of regulated cell death,engages in a complex dialogue between dying CCs and immune cells in the tumor microenvironment(TME),ultimately evoking the damage-associated molecular pattern(DAMP)signals to activate tumor-specific immunity.The ICD inducers mediate the death of CCs and improve both antigenicity and adjuvanticity.At the same time,they reprogram TME with a“cold-warmhot”immune status,ultimately amplifying and sustaining dendritic cell-and T cell-dependent innate sensing as well as the antitumor immune responses.In this review,we discuss how to stimulate ICD based upon the biological properties of CCs that have evolved under diverse stress conditions.Additionally,we highlight how this dynamic interaction contributes to priming tumor immunogenicity,thereby boosting anticancer immune responses.We believe that a deep understanding of these ICD processes will provide a framework for evaluating its vital role in cancer immunotherapy.

关键词： Immunogenic cell death damage-associated molecular pattern tumor immunogenicity antitumor immune responses

Challenges and optimal strategies of CAR T therapy for hematological malignancies

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2023年第3期136卷 269-279页

作者： Yajing Zhang Yang Xu Xiuyong Dang Zeyu Zhu Wenbin Qian Aibin Liang weidong han Department of Bio-Therapeutics The First Medical CentreThe General Hospital of Chinese People’s Liberation ArmyBeijing 100853China Department of Hematology The Second Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhouZhejiang 310009China Department of Hematology Tongji Hospital of Tongji UniversityShanghai 200065China

Remarkable improvement relative to traditional approaches in the treatment of hematological malignancies by chimeric antigen receptor (CAR) T-cell therapy has promoted sequential approvals of eight commercial CAR T products within last 5 years. Although CAR T cells’ productization is now rapidly boosting their extensive clinical application in real-world patients, the limitation of their clinical efficacy and related toxicities inspire further optimization of CAR structure and substantial development of innovative trials in various scenarios. Herein, we first summarized the current status and major progress in CAR T therapy for hematological malignancies, then described crucial factors which possibly compromise the clinical efficacies of CAR T cells, such as CAR T cell exhaustion and loss of antigen, and finally, we discussed the potential optimization strategies to tackle the challenges in the field of CAR T therapy.

关键词： Chimeric antigen receptor Lymphoma Leukemia Multiple myeloma Hematologic malignancies Resistance

Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFNγproduction

在线全文

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2023年第11期20卷 779-782页

作者： Yelei Guo Chuan Tong Zhiqiang Wu Yuting Lu Yao Wang weidong han Department of Bio-therapeutic the First Medical CenterChinese PLA General HospitalBeijing 100853China

Adoptive cell transfer(ACT)using chimeric antigen receptor(CAR)modified T cells and T cell receptor(TCR)engineered T cells has shown therapeutic efficacy in cancer treatment1,2.CAR T cells are widely applicable to tum... 详细信息

关键词： sustained endogenous CAR

Optimal model establishment of whole-process management data for CAR-T therapy in China—how should this be done?

在线全文

学校读者我要写书评

暂无评论

Cellular & Molecular Immunology 2022年第1期19卷 122-124页

作者： Xiaolei Li hanren Dai Xian Li Ping Li Wenbin Qian Aibin Liang weidong han Department of Bio-Therapeutics the First Medical CentreChinese PLA General HospitalBeijingChina Department of Oncology the First Affiliated Hospital of Anhui Medical UniversityHefeiChina Department of Hematology the Second Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhouZhejiangChina Department of Hematology Tongji Hospital of Tongji UniversityShanghaiChina

Chimeric antigen receptor(CAR)T-cell therapy utilizes patients’own T lymphocytes that are engineered to attack cancer cells[1,2,3].With the US Food and Drug Administration(FDA)approval of four CD19-and one BCMA-targeted CAR therapy for B cell malignancies[4,5],CAR T-cell therapy has finally reached the status of a medicinal product.

关键词： CAR lymphocytes utilize

Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2022年第5期7卷 1634-1643页

作者： Xin Yan Deyun Chen Yao Wang Yelei Guo Chuan Tong Jianshu Wei Yajing Zhang Zhiqiang Wu weidong han School of Medicine Nankai UniversityTianjinChina Department of Bio-therapeutic the First Medical CenterChinese PLA General HospitalBeijingChina National Clinical Research Center for Hematologic Diseases the First Affiliated Hospital of Soochow UniversitySuzhouChina

Despite the remarkable success of chimeric antigen receptor(CAR)T-cell therapy for treating hematologic malignancies,resistance and recurrence still occur,while the markers or mechanisms underlying this resistance remain poorly understood.Here,via an unbiased genome-wide CRISPR/Cas9 screening,we identified loss of NOXA,a B-cell lymphoma 2(BCL2)family protein in B-cell malignancies,as a pivotal regulator of resistance to CAR T-cell therapy by impairing apoptosis of tumor cells both in vitro and in vivo.Notably,low NOXA expression in tumor samples was correlated with worse survival in a tandem CD19/20 CAR T clinical trial in relapsed/refractory B-cell lymphoma.

关键词： CRISPR/Cas9 NOXA malignancies

Epi-immunotherapy for cancers:rationales of epi-drugs in combination with immunotherapy and advances in clinical trials

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2022年第6期42卷 493-516页

作者： Yang Xu Ping Li Yang Liu Dijia Xin Wen Lei Aibin Liang weidong han Wenbin Qian Department of Hematology the Second Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhouZhejiang 310009P.R.China Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology Life Sciences InstituteZhejiang UniversityHangzhouZhejiang 310058P.R.China Department of Hematology Tongji Hospital of Tongji UniversityShanghai 200065P.R.China Department of Bio-Therapeutic the First Medical CentreChinese PLA General HospitalBeijing 100853P.R.China

Over the last two decades,several epi-drugs,immune checkpoint inhibitors(ICIs)and adoptive cell therapies have received clinical approval for use in certain types of cancer.However,monotherapy with epi-drugs or ICIs has shown limited efficacy in most cancer patients.Epigenetic agents have been shown to regulate the crosstalk between the tumor and host immunity to alleviate immune evasion,suggesting that epi-drugs can potentially synergize with immunotherapy.In this review,we discuss recent insights into the rationales of incorporating epigenetic therapy into immunotherapy,called epi-immunotherapy,and focus on an update of current clinical trials in both hematological and solid malignancies.Furthermore,we outline the future challenges and strategies in the field of cancer epi-immunotherapy.

关键词： chimeric antigen receptor T cell clinical trial DNA methylation Epi-drug Epiimmunotherapy histone acetylation immune checkpoint.tumor microenvironment vaccine

Cytokine-induced killer (ClK) cells:from basic research to clinical translation

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer 2015年第3期34卷 99-107页

作者： Yelei Guo weidong han Department of Immunology Institute of Basic MedicineChinese PLA General Hospital

The accumulation of basic researches and clinical studies related to cytokine-induced killer(CIK) cells has confirmed their safety and feasibility in treating malignant diseases.This review summarizes the available published literature related to the biological characteristics and clinical applications of CIK cells in recent years.A number of clinical trials with CIK cells have been implemented during the progressive phases of cancer,presenting potential widespread applications of CIK cells for the future.Furthermore,this review briefly compares clinical applications of CIK cells with those of other adoptive immunotherapeutic cells.However,at present,there are no uniform criteria or large-scale preparations of CIK cells.The overall clinical response is difficult to evaluate because of the use of autologous CIK cells.Based on these observations,several suggestions regarding uniform criteria and universal sources for CIK cell preparations and the use of CIK cells either combined with chemotherapy or alone as a primary strategy are briefly proposed in this review.Large-scale,controlled,grouped,and multi-center clinical trials on CIK cell-based immunotherapy should be conducted under strict supervision.These interventions might help to improve future clinical applications and increase the clinical curative effects of CIK cells for a broad range of malignancies in the future.

关键词：细胞因子临床应用基础研究 CLK 杀伤诱导恶性肿瘤细胞翻译

CART trials are going ahead

在线全文

学校读者我要写书评

暂无评论

Science China(Life Sciences) 2017年第11期60卷 1276-1279页

作者： jianshu wei weidong han deparment of molecules&immunology chinese pla general hospitalmedical college of plaBeijing 100853China

For a long time,unresectable tumors were mainly controlled by chemotherapy,radiation therapy or kinase inhibitors,with which complete and durable remission was infrequent despite great advances achieved.Until recently,together with checkpoint inhibitors,chimeric antigen receptor modified T(CART)therapies have made immunotherapy percolated into the mainstream of cancer treatment due to astonishing clinical results.

关键词： checkpoint mainstream immunotherapy ahead remission advances despite have companies likely

Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment

在线全文

学校读者我要写书评

暂无评论

Protein & Cell 2017年第12期8卷 896-925页

作者： Zhenguang Wang Yelei Guo weidong han Molecular & Immunological Department Bio-therapeutic Department Chinese PLA General Hospital Beijing 100853 China

Chimeric antigen receptor （CAR） is a recombinant immunoreceptor combining an antibody-derived target- ing fragment with signaling domains capable of acti- vating cells, which endows T cells with the ability to recognize tumor-associated surface antigens indepen- dent of the expression of major histocompatibiiity complex （MHC） molecules. Recent early-phase clinical trials of CAR-modified T （CAR-T） cells for relapsed or refractory B cell malignancies have demonstrated promising results （that is, anti-CD19 CAR-T in B cell acute lymphoblastic leukemia （B-ALL））. Given this suc- cess, broadening the clinical experience of CAR-T cell therapy beyond hematological malignancies has been actively investigated. Here we discuss the basic design of CAR and review the clinical results from the studies of CAR-T cells in B cell leukemia and lymphoma, and several solid tumors. We additionally discuss the major challenges in the further development and strategies for increasing anti-tumor activity and safety, as well as for successful commercial translation.

关键词： chimeric antigen receptor CAR-T,engineered T cells adoptive cell therapy cancer treatment